In early January 2026, Danaher announced ahead of the J.P. Morgan Healthcare Conference that it expects fourth-quarter 2025 revenue and full-year non-GAAP adjusted diluted EPS to finish toward the ...

Through its Danaher Business System, Danaher aims for continuous improvement of its scientific technology portfolio by seeking out attractive markets and then making acquisitions to enter or expand ...

With tariff rules finalized and inventories depleted, there’s light at the end of the tunnel for the medical and scientific ...

Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2025 performance in a ...

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly ...

Vontier’s business model is an iteration of the Danaher Business System playbook, which the firm inherited from its former parent companies, Danaher and Fortive. Vontier Business System focuses on ...

Danaher (DHR) is an American global conglomerate with a strong presence in the life sciences and diagnostics industries. It’s an under-the-radar compounder that has consistently grown over the past ...

Danaher's biotechnology growth prospects look assured. Guidance for 2026 is merely within the range of current market expectations. 10 stocks we like better than Danaher › Shares in biotechnology, ...

We came across a bullish thesis on Danaher Corporation on Heavy Moat Investments’s Substack. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation’s share was trading at ...